SPECTRUM PHARMACEUTICALS INC (SPPI)
US84763A1088 - Common Stock
Taking everything into account, SPPI scores 2 out of 10 in our fundamental rating. SPPI was compared to 588 industry peers in the Biotechnology industry. SPPI has a bad profitability rating. Also its financial health evaluation is rather negative. SPPI has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year SPPI has reported negative net income.
SPPI had a negative operating cash flow in the past year.
In the past 5 years SPPI always reported negative net income.
In the past 5 years SPPI always reported negative operating cash flow.
1.2 Ratios
The profitability ratios for SPPI are negative, so there is not much use analyzing them.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SPPI has a Gross Margin of 32.34%. This is in the better half of the industry: SPPI outperforms 75.42% of its industry peers.
The Profit Margin and Operating Margin are not available for SPPI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 32.34% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SPPI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SPPI has been increased compared to 1 year ago.
Compared to 5 years ago, SPPI has more shares outstanding
SPPI has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -14.02, we must say that SPPI is in the distress zone and has some risk of bankruptcy.
SPPI's Altman-Z score of -14.02 is on the low side compared to the rest of the industry. SPPI is outperformed by 86.78% of its industry peers.
A Debt/Equity ratio of 1.08 is on the high side and indicates that SPPI has dependencies on debt financing.
With a Debt to Equity ratio value of 1.08, SPPI is not doing good in the industry: 83.05% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.08 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -14.02 |
ROIC/WACCN/A
WACC8.97%
2.3 Liquidity
SPPI has a Current Ratio of 2.71. This indicates that SPPI is financially healthy and has no problem in meeting its short term obligations.
SPPI's Current ratio of 2.71 is on the low side compared to the rest of the industry. SPPI is outperformed by 76.44% of its industry peers.
SPPI has a Quick Ratio of 2.38. This indicates that SPPI is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.38, SPPI is not doing good in the industry: 77.80% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.71 | ||
| Quick Ratio | 2.38 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 58.62% over the past year.
EPS 1Y (TTM)58.62%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
SPPI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.88% yearly.
Based on estimates for the next years, SPPI will show a very strong growth in Revenue. The Revenue will grow by 98.74% on average per year.
EPS Next Y88.67%
EPS Next 2Y51.91%
EPS Next 3Y39.88%
EPS Next 5YN/A
Revenue Next Year722.64%
Revenue Next 2Y275.85%
Revenue Next 3Y179.1%
Revenue Next 5Y98.74%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SPPI. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 7.97, the valuation of SPPI can be described as very cheap.
SPPI's Price/Forward Earnings ratio is rather cheap when compared to the industry. SPPI is cheaper than 98.98% of the companies in the same industry.
SPPI is valuated cheaply when we compare the Price/Forward Earnings ratio to 21.63, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 7.97 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
SPPI's earnings are expected to grow with 39.88% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y51.91%
EPS Next 3Y39.88%
5. Dividend
5.1 Amount
SPPI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
SPECTRUM PHARMACEUTICALS INC
NASDAQ:SPPI (7/31/2023, 7:00:02 PM)
After market: 1.04 +0.01 (+0.97%)1.03
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap211.40M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 7.97 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 32.34% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.08 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.71 | ||
| Quick Ratio | 2.38 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)58.62%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y88.67%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y